- Previous Close
1.2200 - Open
1.2300 - Bid 1.2400 x --
- Ask 1.2600 x --
- Day's Range
1.2300 - 1.2800 - 52 Week Range
0.4800 - 2.9800 - Volume
31,405 - Avg. Volume
82,182 - Market Cap (intraday)
98.479M - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3800 - Earnings Date Feb 12, 2025 - Feb 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.38
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
www.medicenna.comRecent News: MDNA.TO
View MorePerformance Overview: MDNA.TO
Trailing total returns as of 2/6/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDNA.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDNA.TO
View MoreValuation Measures
Market Cap
98.48M
Enterprise Value
68.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.91
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.80%
Return on Equity (ttm)
-105.43%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-26.24M
Diluted EPS (ttm)
-0.3800
Balance Sheet and Cash Flow
Total Cash (mrq)
35.63M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-30.38k